Authors: Paul Sanghera1, Wenyu Liu2, Piers Gaunt2, Charlotte Firth2, Isla Humphreys2, Andrew Hartley1, Mehmet Sen3, Anthony Kong4, Devraj Srinivasan5, Rafael Moleron6, Konstantinos Geropantas7, Andrew Chan8, Lorcan O'Toole9, Hoda Booz10, Muthiah Sivaremalingam11, Jim Lester12, Bernadette Foran13, Charles Fong1, Tom Roques14, Rita Simoes15, Zohal Nabi15, Hisham Mehanna16
1University Hospitals Birmingham NHS Trust, Oncology, Birmingham, United Kingdom; 2Institute of Cancer and Genomic Sciences, University of Birmingham, Cancer Research Clinical Trials Unit, Birmingham, United Kingdom; 3St. James's Institute of Oncology, Clinical Oncology, Leeds, United Kingdom; 4Kings College London, Comprehensive Cancer Centre, London, United Kingdom; 5Edinburgh Cancer Centre, Clinical Oncology, Edinburgh, United Kingdom; 6Aberdeen Royal Infirmary, Clinical Oncology, Aberdeen, United Kingdom; 7Norfolk & Norwich University Hospitals NHS FT, Oncology, Norwich, United Kingdom; 8University Hospitals Coventry and Warwickshire, Arden Cancer Centre, Coventry, United Kingdom; 9Queen’s Centre for Oncology, Clinical Oncology, Cottingham, Hull, United Kingdom; 10University Hospitals Bristol NHS Foundation Trust, Oncology, Bristol, United Kingdom; 11Royal Preston Hospital, Oncology, Preston, United Kingdom; 12Weston Park Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Clinical Oncology, Sheffield , United Kingdom; 13Weston Park Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Clinical Oncology, Sheffield, United Kingdom; 14Norfolk & Norwich University Hospitals NHS FT, Clinical Oncology, Norwich, United Kingdom; 15National Radiotherapy Trials Quality Assurance Group (RTTQA), Radiotherapy Physics, Mount Vernon Cancer Centre, Middlesex, United Kingdom; 16Institute of Cancer and Genomic Sciences, University of Birmingham, Institute of Head and Neck Studies and Education, Birmingham, United Kingdom
Show Affiliations
Hide Affiliations